Literature DB >> 1759092

Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.

M H Kryger1, D Steljes, Z Pouliot, H Neufeld, T Odynski.   

Abstract

There is little published literature on the correlation between subjective and objective efficacy of hypnotics. We wanted to determine whether there was a correlation between the patient's subjective evaluation of the efficacy of the hypnotic with the polysomnographic (PSG) findings. We studied 16 patients with chronic insomnia (sleep latency, greater than or equal to 30 minutes; total sleep time, greater than 240 but less than 420 minutes) for 11 nights who took placebos on nights 1 and 2, zolpidem (imidazopyridine) on nights 3-9 and placebo on nights 10 and 11. Patients completed a questionnaire each morning following PSG, which evaluated subjective sleep quality, sleep latency and total sleep time. These data were compared to PSG findings to answer specific questions about sleep latency reduction, efficacy of the hypnotic after a week's use, sleep quality after discontinuing the drug, and any correlation between subjective and objective measures. PSG findings indicated a shortened sleep latency, increased total sleep time, decreased total wake time and increased sleep efficiency when patients ingested zolpidem 30 minutes before bedtime. We found that after 7 nights (nights 3-9) the drug was still effective in reducing sleep latency and increasing total sleep time. Upon withdrawal (nights 10 and 11) sleep returned to baseline (nights 1 and 2). Subjectively, the patients confirmed those findings on the questionnaire, as well as a subjective reduction in the number of awakenings and, interestingly, a subjective increase in the time spent awake after sleep. Many of the objective variables we examined correlated highly with the subjective variables. While on zolpidem, subjects believed and were objectively shown to have a decreased sleep latency, increased total sleep time and decreased time awake before persistent sleep, although they tended to overestimate sleep latency and time spent awake before persistent sleep and underestimated total sleep time. Although the correlation between objective and subjective measures was high for the group, in individual patients there was an impressive difference between the two, and the highest coefficient of variation between a subjective and objective measures was 0.453. No correlations were found with subjective measures of refreshing quality of sleep, decrease in number of awakenings, how sleepy patients felt in the morning or their ability to concentrate in the morning. Thus, we believe the PSG remains the keystone in the evaluation of hypnotic efficacy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759092     DOI: 10.1093/sleep/14.5.399

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  15 in total

1.  Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bienfait; Allison Dicke; Cynthia L Comella; Charles Cantor; Lee Hyer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

Review 2.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

3.  Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies.

Authors:  D Alan Lankford; Bruce C Corser; Yan-Ping Zheng; Zhengrong Li; Duane B Snavely; Christopher R Lines; Steve Deacon
Journal:  Sleep       Date:  2008-10       Impact factor: 5.849

4.  Sleeping Pill Administration Time and Patient Subjective Satisfaction.

Authors:  Seockhoon Chung; Soyoung Youn; Kikyoung Yi; Boram Park; Suyeon Lee
Journal:  J Clin Sleep Med       Date:  2016-01       Impact factor: 4.062

Review 5.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

Review 6.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

7.  EEG profile of intravenous zolpidem in healthy volunteers.

Authors:  A Patat; S Trocherie; J J Thebault; P Rosenzweig; C Dubruc; G Bianchetti; L A Court; P L Morselli
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 8.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.

Authors:  Surilla Randall; Timothy A Roehrs; Thomas Roth
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

10.  Effects of eszopiclone and zolpidem on sleep and waking states in the adult guinea pig.

Authors:  Mingchu Xi; Michael H Chase
Journal:  Sleep       Date:  2008-07       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.